The role of breast cancer resistance protein in acute lymphoblastic leukemia.

Sabine Plasschaert(Princess Máxima Center), Elisabeth G.E. de Vries(Karolinska University Hospital), Eveline S.J.M. de Bont(Hôpital Saint-Michel), Edo Vellenga(University Medical Center Groningen), Willem A. Kamps(Pediatric Oncology Group), George L. Scheffer(University of Amsterdam), Kuniaki Morisaki, Susan E. Bates(The Nature Conservancy), Rik J. Scheper(Unknown), Dorina M. van der Kolk
PubMed
November 1, 2003
Cited by 49

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772